← board
AKTX
distress 9/10 · high distress / dilution risk$9.50-3%today-79% from 52w high
Lead: cancer
Revenue
pre-revenue
Liquidity
$3M
Runway
0.3 yrs
Shares 1y
+40%
Price & events
-11.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.2%
1D
-17.4%
1W
-19.4%
1M
+58.3%
3M
-13.3%
6M
-79.1%
1Y
-94.2%
2Y
-99.3%
5Y
-99.3%
All
Overview
- Market Cap
- $869.90B
- Volume
- 7.28K
- 52 Week Range
- $3.06 – $45.40
- Total Shares
- 91.57B
- Float Shares
- 704.67K
- Short %
- 1.96%
- % Held by Insiders
- 16.80%
- % Held by Institutions
- 9.40%
- RVOL
- 0.09x
- Beta
- 1.39
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 2
- late 2026/early 2027Guided 55%trial initiationsecondaryPhase 1AKTX-101 · First-in-human trial initiationSEC 8-K
- 2024-11-07partnershipShareholders approved merger with Peak Bio.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-07-20Maxim GroupHold → Buy
- 2026-04-08Maxim GroupBuy → Hold
- 2026-04-01HC Wainwright & Co.Buy
- 2026-01-05Ladenburg ThalmannBuy
- 2025-09-09HC Wainwright & Co.Buy
- 2025-07-18Maxim GroupBuy
Competitors — cancer
- ABBVAbbVie Inc.$451.1B · D2
- MRKMerck & Co., Inc.$318.8B · D3
- NVSEFNOVARTIS AG$292.0B · D3
- AMGNAMGEN INC$195.4B · D3
- PFEPFIZER INC$142.2B · D3
- BNTXBioNTech SE$23.1B · D1
- OLMAOlema Pharmaceuticals, Inc.$990M · D4
- CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
- BCYCBICYCLE THERAPEUTICS PLC$124M · D4
- AZNASTRAZENECA PLC— · D3
Recent news
- 2026-07-22Price to book forward of Akari Therapeutics Plc – NASDAQ:AKTX - TradingView
- 2026-07-22Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity - Yahoo Finance UK
- 2026-07-21Akari and Whitehawk collaborate on ADC research - BioWorld News
- 2026-07-21Akari Therapeutics partners with Whitehawk on dual payload study - Investing.com
- 2026-07-21Akari Therapeutics partners with Whitehawk on dual payload study By Investing.com - Investing.com Canada
- 2026-07-21Akari Therapeutics Announces Strategic Preclinical Research Collaboration with Whitehawk Therapeutics on Dual-Payload ADC Development - Quiver Quantitative
- 2026-07-21Akari and Whitehawk to Test Two ADC Payloads in Preclinical Studies - Stock Titan
- 2026-07-21Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics - GlobeNewswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.